Phase 2 Ovarian Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are in generally good health and able to carry out daily activities with little or no limitation (this is measured on a standard scale called ECOG, scoring 0 or 1)
- You have been diagnosed with a specific type of ovarian, fallopian tube, or peritoneal cancer called high-grade serous epithelial cancer
- In most cases, your cancer must have at least one tumor that can be clearly measured on a scan
- Any previous cancer treatment (such as chemotherapy) must have finished at least 4 weeks ago (or sooner, depending on the specific drug used)
- If you received targeted radiation therapy, it must have been completed at least 2 weeks before starting this trial
Who may not be able to join:
- You have a type of ovarian cancer classified as endometrioid, clear cell, mucinous, sarcomatous, mixed, low-grade, or borderline (confirm with trial site)
- You have a significant medical condition or other health issue that the trial doctor believes could interfere with your participation or make the treatment unsafe for you
- You have previously received a treatment that targets a protein called FRα (folate receptor alpha) (confirm with trial site)
- You have previously had large-area radiation therapy that affected more than 20% of your bone marrow
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: ABBVIE INC., AbbVie
Phone: 844-663-3742
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Participants With Dose-limiting Toxicities (DLTs); Percentage of Participants with Adverse Events (AE)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.